On 27 June 2013 the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a variation to the terms of the marketing authorisation for the medicinal product Onglyza. The marketing authorisation holder for this medicinal product is Bristol-Myers Squibb/AstraZeneca EEIG. They may request a re-examination of the CHMP opinion, provided that they notify the European Medicines Agency in writing of their intention within 15 days of receipt of the opinion.

The CHMP adopted a new indication as follows:
"Onglyza is indicated in adult patients aged 18 years and older with type 2 diabetes mellitus to improve glycaemic control: as monotherapy in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance".

Detailed conditions for the use of this product will be described in the updated summary of product characteristics (SmPC), which will be published in the revised European public assessment report (EPAR), and will be available in all official European Union languages after the variation to the marketing authorisation has been granted by the European Commission.

For information, the full indications for Onglyza will be as follows:

Onglyza is indicated in adult patients aged 18 years and older with type 2 diabetes mellitus to improve glycaemic control:

- as monotherapy
  - in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance

as dual oral therapy in combination with
• metformin, when metformin alone, with diet and exercise, does not provide adequate glycaemic control.

• a sulphonylurea, when the sulphonylurea alone, with diet and exercise, does not provide adequate glycaemic control in patients for whom use of metformin is considered inappropriate.

• a thiazolidinedione, when the thiazolidinedione alone with diet and exercise, does not provide adequate glycaemic control in patients for whom use of a thiazolidinedione is considered appropriate.

as triple oral therapy in combination with

• metformin plus a sulphonylurea when this regimen alone, with diet and exercise, does not provide adequate glycaemic control.

as combination therapy with insulin (with or without metformin), when this regimen alone, with diet and exercise, does not provide adequate glycaemic control.